97 related articles for article (PubMed ID: 24555961)
61. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
62. Safety evaluation of olaparib for treating ovarian cancer.
Lheureux S; Bowering V; Karakasis K; Oza AM
Expert Opin Drug Saf; 2015 Aug; 14(8):1305-16. PubMed ID: 26051946
[TBL] [Abstract][Full Text] [Related]
63. Olaparib, PARP1 inhibitor in ovarian cancer.
Marchetti C; Imperiale L; Gasparri ML; Palaia I; Pignata S; Boni T; Bellati F; Benedetti Panici P
Expert Opin Investig Drugs; 2012 Oct; 21(10):1575-84. PubMed ID: 22788971
[TBL] [Abstract][Full Text] [Related]
64. [Research progresses of the PARP inhibitors for the treatment of cancer].
He YJ; Liu RH; Ning CQ; Yu NF
Yao Xue Xue Bao; 2013 May; 48(5):655-60. PubMed ID: 23888686
[TBL] [Abstract][Full Text] [Related]
65. Olaparib: first global approval.
Deeks ED
Drugs; 2015 Feb; 75(2):231-40. PubMed ID: 25616434
[TBL] [Abstract][Full Text] [Related]
66. PARP inhibition and synthetic lethality in ovarian cancer.
Eskander RN; Tewari KS
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):613-22. PubMed ID: 24984781
[TBL] [Abstract][Full Text] [Related]
67. PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.
Kruse V; Rottey S; De Backer O; Van Belle S; Cocquyt V; Denys H
Acta Clin Belg; 2011; 66(1):2-9. PubMed ID: 21485757
[TBL] [Abstract][Full Text] [Related]
68. BRCA mutations in the management of breast cancer: the state of the art.
Narod SA
Nat Rev Clin Oncol; 2010 Dec; 7(12):702-7. PubMed ID: 20956982
[TBL] [Abstract][Full Text] [Related]
69. PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.
Mukhopadhyay A; Curtin N; Plummer R; Edmondson RJ
BJOG; 2011 Mar; 118(4):429-32. PubMed ID: 21244617
[TBL] [Abstract][Full Text] [Related]
70. [Hereditary ovarian cancer. The role of BRCA1 gene dysfunction in response to chemotherapy].
Blecharz P; Karolewski K; Urbański K
Ginekol Pol; 2011 Mar; 82(3):214-20. PubMed ID: 21735691
[TBL] [Abstract][Full Text] [Related]
71. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.
Frampton JE
BioDrugs; 2015 Apr; 29(2):143-50. PubMed ID: 25899311
[TBL] [Abstract][Full Text] [Related]
72. Leveraging DNA repair deficiency in gynecologic oncology.
Walsh CS; Hodeib M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):24-31. PubMed ID: 26694829
[TBL] [Abstract][Full Text] [Related]
73. Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.
Gartner EM; Burger AM; Lorusso PM
Cancer J; 2010; 16(2):83-90. PubMed ID: 20404603
[TBL] [Abstract][Full Text] [Related]
74. [PARP inhibitors to treat triple negative breast cancer].
Sugie T
Gan To Kagaku Ryoho; 2010 Dec; 37(13):2850-5. PubMed ID: 21235091
[No Abstract] [Full Text] [Related]
75. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.
Friedlander M; Banerjee S; Mileshkin L; Scott C; Shannon C; Goh J
Asia Pac J Clin Oncol; 2016 Dec; 12(4):323-331. PubMed ID: 27917619
[TBL] [Abstract][Full Text] [Related]
76. Hereditary ovarian cancer: biology, response to chemotherapy and prognosis.
Safra T
Womens Health (Lond); 2009 Sep; 5(5):543-53. PubMed ID: 19702453
[TBL] [Abstract][Full Text] [Related]
77. Synthetic lethal approaches to breast cancer therapy.
Rehman FL; Lord CJ; Ashworth A
Nat Rev Clin Oncol; 2010 Dec; 7(12):718-24. PubMed ID: 20956981
[TBL] [Abstract][Full Text] [Related]
78. Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
Burgess BT; Kolesar JM
Am J Health Syst Pharm; 2018 Nov; 75(21):1697-1707. PubMed ID: 30228165
[TBL] [Abstract][Full Text] [Related]
79. Molecular/genetic therapies in ovarian cancer: future opportunities and challenges.
Ziebarth AJ; Landen CN; Alvarez RD
Clin Obstet Gynecol; 2012 Mar; 55(1):156-72. PubMed ID: 22343235
[TBL] [Abstract][Full Text] [Related]
80. Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target.
Goyal G; Fan T; Silberstein PT
Fam Cancer; 2016 Jul; 15(3):359-66. PubMed ID: 26873719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
